U.S. drug advisers backed Onyx Pharmaceuticals Inc's drug for patients who have
failed to successfully treat their blood cancer with other medicines, making it
likely the drug would secure approval from U.S. regulators.
A panel of
outside advisers to the Food and Drug Administration voted unanimously to
recommend approval of Asics Gel Lyte III Onyx's drug, to be sold as Kyprolis,
for treating multiple myeloma in people who have tried at least two other
medicines.
The FDA usually cheap tiger shoes follows panel
recommendations, although it is Asics Gel Virage 4 not required to, and will
make a final decision by July 27.
Multiple myeloma, a type of cancer that
affects the plasma cells in bone marrow, is relatively rare in the asics
onitsuka tiger United States but often deadly. In 2012, about 21,700 new cases
of multiple myeloma will be diagnosed in the United States, and about 10,710
people will die from the disease, according to the American Cancer
Society.
Analysts expect the multiple myeloma market to reach $5.4
billion Onitsuka Tiger Mini Cooper by 2016, with carfilzomibthe chemical name of
Kyprolisgarnering about $570 million if it is approved, according asics tiger to
Thomson Reuters forecasts.
Onyx shares Asics Tiger California 78 were
halted during the panel's discussion and vote. Shares of Ligand Pharmaceuticals
Inca small biotech firm that contributed to asics tigers Kyprolis and would
receive royalties from its salesclosed up 12.8 percent at $14.55.
Panel
members said the drug gave people another option to try to beat back the
disease.
"I do think this drug is beneficial to this patient population
given the limited therapeutic options available," Onitsuka Tiger Kanuchi said
panel member Dr. Michael Menefee, assistant professor in hematology and oncology
at the Mayo Clinic.
The Onyx drug is a proteasome inhibitor with the same
mechanism of action as Takeda Pharmaceutical Co Ltd's Velcade, or bortezomib, a
commonly New Mens Asics Mexico 66 used treatment for multiple myeloma available
since 2003.
Onyx said about a asics
tiger
fifth of all myeloma patients have cancer that no longer responds to
standard drugs, leaving room for another option. The company is seeking approval
in only those people who have already tried at least two other myeloma
treatments, including Velcade and Celgene Corp's Revlimid or Thalomid, known
chemically as thalidomide.